Trials / Unknown
UnknownNCT02334293
Omegaven® as Parenteral Nutrition
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Carle Foundation Hospital · Academic / Other
- Sex
- All
- Age
- 14 Days – 4 Months
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if a fat emulsion comprised of omega-3 fatty acids, Omegaven, would be beneficial in the management of steatotic liver injury in parenteral nutrition (PN) by its inhibition of de novo lipogenesis, the reduction of arachidonic acid-derived inflammatory mediators, prevention of essential fatty acid deficiency through the presence of small amounts of arachidonic acid, and improved clearance of lipids from the serum.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Omegaven | Omegaven® fat emulsion will be used as a Compassionate Use treatment for critically ill infants with PN associated liver injury. |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2017-07-01
- First posted
- 2015-01-08
- Last updated
- 2015-01-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02334293. Inclusion in this directory is not an endorsement.